Developmental Genotype-Tissue Expression Project vs Freenome
Developmental Genotype-Tissue Expression Project vs Freenome, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Developmental Genotype-Tissue Expression Project is on 51/100 and Freenome on 59/100.
Where each one leads
Developmental Genotype-Tissue Expression Project
Leads on none of the measures we hold for both companies.
Freenome
- our overall score: 59/100 against 51/100
- agent readiness: 46/100 against 37/100
- funding raised: $570M against $38.5M
At a glance
| Measure | Developmental Genotype-Tissue Expression Project | Freenome |
|---|---|---|
| What it is | Establishing the first comprehensive database of healthy pediatric tissue gene expression to understand genetic influences on childhood development and diseases. | Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology. |
| Category | Biotechnology, Healthcare, Genomics, Data Science | Biotechnology, Healthcare, Artificial Intelligence, Biotech |
| Sells toBusiness model | B2G | B2B |
| Offering | Platform | Services |
| Founded | 2021 | 2014 |
| Headquarters | Philadelphia, United States | South San Francisco, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Developmental Genotype-Tissue Expression Project | Freenome |
|---|---|---|
| Employees | Not published | 402 |
| Total funding | $38.5M | $570M |
| Latest round | Grant | Series D |
| Valuation | Not published | $1.1B |
| LinkedIn followers | Not published | 46,860 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Developmental Genotype-Tissue Expression Project | Freenome |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 51/100 | 59/100 |
| Traction | 38/100 | 60/100 |
| Team | 30/100 | Not published |
| Search visibility | Not published | 31/100 |
| Quality | 68/100 | 78/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (37/100) | D (46/100) |
| Domain ratingLink authority, 0-100 | Not published | 56/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Developmental Genotype-Tissue Expression Project | Freenome |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Tag Manager |
| Support stack | Not detected | HubSpot |
Developmental Genotype-Tissue Expression Project vs Freenome: common questions
Which is better, Developmental Genotype-Tissue Expression Project or Freenome?
On our 0-100 score Freenome rates higher (59/100 against 51/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Developmental Genotype-Tissue Expression Project and Freenome compare on the numbers?
Freenome leads on our overall score (59/100 against 51/100), agent readiness (46/100 against 37/100), funding raised ($570M against $38.5M).
Read the full Developmental Genotype-Tissue Expression Project review and pricing or the Freenome review and pricing. You can also browse other Developmental Genotype-Tissue Expression Project alternatives we track.